Trial Profile
A Randomized, Double Blind, Parallel-Group Comparison Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Inc
- 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.